TG Therapeutics | TGTX - Ebitda


TG Therapeutics reported $28.11M in EBITDA for its fiscal quarter ending in March of 2026.





Ebitda Change Date
AbbVie USD 3.69B 1.68B Mar/2026
Alaunos Therapeutics USD -21.02M 1.33M Mar/2021
Amgen USD 3.86B 1.28B Mar/2026
Ardelyx USD -29.77M 35.79M Mar/2026
Arrowhead Research USD -107.35M 164.52M Mar/2026
Bayer EUR 2.14B 2.31B Jun/2026
Biogen USD 649.7M 76.5M Mar/2026
Corcept Therapeutics USD -49M 53.2M Mar/2026
Curis USD -12.3M 231K Sep/2023
Gilead Sciences USD 3.51B 489M Mar/2026
J&J USD 8.27B 1.08B Mar/2026
Karyopharm Therapeutics USD -26.2M 1.83M Sep/2024
Novartis USD 6.48B 1.19B Jun/2026
Novavax USD 19.36M 190.79M Dec/2025
PTC Therapeutics USD 61.98M 132.97M Mar/2026
Puma Biotechnology USD 729K 11.36M Jun/2024
Regeneron Pharmaceuticals USD 1.66B 695.2M Jun/2026
Roche Holding CHF 13.43B 744M Jun/2026
TG Therapeutics USD 28.11M 23.58M Mar/2026
Vertex Pharmaceuticals USD 1.19B 195.3M Mar/2026